Natural Phenomenon or Process – Page 9

Relay Therapeutics Announces 10% Workforce Reduction to Streamline Research Organization

8 months ago talkbio0Tagged Relay Therapeutics, Research Organization

Relay Therapeutics, layoffs, workforce reduction, biotech, research organization, streamlining

Pharmaceutical Giants J&J, Bayer, and Pfizer Announce Layoffs Affecting Nearly 500 Employees

9 months ago talkbio0Tagged Bayer, Biotech Layoffs, Drug Industry, Johnson & Johnson, layoffs, Pfizer

Layoffs, Pharmaceutical Industry, Johnson & Johnson, Bayer, Pfizer, Biotech Layoffs, Workforce Reduction

IGM Biosciences Undergoes Strategic Pivot to Autoimmune Diseases, Overhauls Leadership and Reduces Workforce

9 months ago talkbio0Tagged Autoimmune Diseases, Biosciences, Changing, Immunoglobulin M, imvotamab, Leadership, strategic pivot, T cell-engaging IgM antibodies

IGM Biosciences, autoimmune diseases, strategic pivot, T cell-engaging IgM antibodies, leadership changes, workforce reduction, imvotamab, IGM-2644

Shattuck Labs Shifts Focus to IBD Drug, Discontinues CD47 Program and Reduces Workforce by 40%

9 months ago talkbio0Tagged Antibodies, CD47 Antigen, Inflammatory Bowel Diseases, Laboratory test finding, Programs - Publication Format, Shattuck, SL 325, TNFRSF25 gene

Shattuck Labs, CD47 program, workforce reduction, IBD drug, SL-325, DR3 antagonist antibody

Enanta Pharmaceuticals Achieves Breakthrough in RSV Treatment with EDP-323, Demonstrating Significant Reductions in Viral Load and Symptoms

9 months ago talkbio0Tagged Alleviation, antiviral treatment, EDP-323, Enanta, Human Challenge Study, phase 2a, Respiratory syncytial virus, Symptoms, Viral Load result

Enanta Pharmaceuticals, EDP-323, Respiratory Syncytial Virus (RSV), Antiviral Treatment, Phase 2a Human Challenge Study, Viral Load Reduction, Symptom Alleviation

Bristol Myers Squibb Continues Layoffs, Cutting 79 More Jobs in New Jersey Amid $1.5B Cost Reduction Effort

9 months ago talkbio0Tagged Drug Industry, Financial cost, Myers, New Jersey, squibb

Bristol Myers Squibb, layoffs, New Jersey, cost reduction, pharmaceutical industry

Aligos Therapeutics Reports Positive Phase IIa Results for MASH Treatment, Despite Investor Skepticism

9 months ago talkbio0Tagged ALG-055009, Aligos, Effect, investor, liver fat, MASH, metabolic dysfunction-associated steatohepatitis, Placebos, Skepticism, Trial Phase 2A

Aligos Therapeutics, MASH (Metabolic Dysfunction-Associated Steatohepatitis), Phase IIa trial, ALG-055009, Liver fat reduction, Investor skepticism, Placebo effect